Maze Therapeutics, Inc.
MAZE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $167,500 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $167,500 | $0 | $0 |
| % Margin | 100% | – | – |
| R&D Expenses | $83,496 | $73,945 | $88,192 |
| G&A Expenses | $26,418 | $24,606 | $22,834 |
| SG&A Expenses | $26,418 | $24,606 | $22,834 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $109,914 | $98,551 | $111,026 |
| Operating Income | $57,586 | -$98,551 | -$111,026 |
| % Margin | 34.4% | – | – |
| Other Income/Exp. Net | -$4,183 | -$1,864 | -$3,914 |
| Pre-Tax Income | $53,403 | -$100,415 | -$114,940 |
| Tax Expense | $1,172 | $0 | $0 |
| Net Income | $52,231 | -$100,415 | -$114,940 |
| % Margin | 31.2% | – | – |
| EPS | 0.078 | -2.294 | -2.626 |
| % Growth | 103.4% | 12.6% | – |
| EPS Diluted | 0.078 | -2.294 | -2.626 |
| Weighted Avg Shares Out | 43,796 | 43,777 | 43,777 |
| Weighted Avg Shares Out Dil | 43,796 | 43,777 | 43,777 |
| Supplemental Information | – | – | – |
| Interest Income | $4,654 | $1,966 | $2,028 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $3,297 | $4,089 | $3,820 |
| EBITDA | $60,883 | -$94,462 | -$107,206 |
| % Margin | 36.3% | – | – |